Overview

Safety and Efficacy of Liraglutide in Parkinson's Disease

Status:
Active, not recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the efficacy and safety of liraglutide in the treatment of patients with idiopathic Parkinson's disease (PD).
Phase:
Phase 2
Details
Lead Sponsor:
Cedars-Sinai Medical Center
Collaborators:
Novo Nordisk A/S
The Cure Parkinson's Trust
Treatments:
Liraglutide